<unk>  (marketed under the brand names Meilax, Ronlax and Victan) is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. In animal studies it was found to have low toxicity, although in rats evidence of pulmonary phospholipidosis occurred with pulmonary foam cells developing with long-term use of very high doses. Its elimination half-life is 51–103 hours. Its mechanism of action is similar to other benzodiazepines.<unk>  also produces an active metabolite which is stronger than the parent compound.<unk>  was designed to be a prodrug for descarboxyloflazepate, its active metabolite. It is the active metabolite which is responsible for most of the pharmacological effects rather than<unk> . The main metabolites of<unk>  are descarbethoxyloflazepate,<unk>  and 3-hydroxydescarbethoxyloflazepate. Accumulation of the active metabolites of<unk>  are not affected by those with kidney failure or impairment. The symptoms of an overdose of<unk>  include sleepiness, agitation and ataxia. Hypotonia may also occur in severe cases. These symptoms occur much more frequently and severely in children. Death from therapeutic maintenance doses of<unk>  taken for 2 – 3 weeks has been reported in 3 elderly patients. The cause of death was asphyxia due to benzodiazepine toxicity. High doses of the antidepressant fluvoxamine may potentiate the adverse effects of<unk> .<unk>  is commercialized in Mexico, under the trade name Victan. It is officially approved for the following conditions: *Anxiety *Post-trauma anxiety *Anxiety associated with severe neuropathic pain *Generalized anxiety disorder (GAD) *Obsessive–compulsive disorder *Panic attack *Delirium tremens
Ethyl loflazepate
Haloxazolam
Triazolam
Adinazolam
Halazepam
Fludiazepam
Flutazolam
Remimazolam